Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AZD8931 diFuMaric acid 是一种可逆的 ATP 竞争性 EGFR、ErbB2 和 ErbB3 抑制剂(IC50 分别为 4 nM、3 nM 和 4 nM)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,300 | 现货 | ||
5 mg | ¥ 2,920 | 现货 | ||
10 mg | ¥ 4,320 | 现货 | ||
25 mg | ¥ 6,890 | 现货 | ||
50 mg | ¥ 9,330 | 现货 | ||
100 mg | ¥ 12,500 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 4,130 | 现货 |
产品描述 | AZD8931 is a reversible and ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 (IC50 of 4 nM, 3 nM and 4 nM, respectively). |
靶点活性 | ErbB3:4 nM, ErbB2:3 nM , EGFR:4 nM |
体内活性 | AZD8931 significantly suppressed cell growth of IBC cells and induced apoptosis of human IBC cells in vitro.AZD8931 monotherapy inhibited xenograft growth[1]. |
动物实验 | Two IBC cell lines SUM149 and FC-IBC-02 。Cell growth and apoptotic cell death were examined in vitro.?For the in vivo tumor growth studies, IBC cells were orthotopically transplanted into the mammary fat pads of immunodeficient mice.?AZD8931 was given by daily oral gavage at doses of 25 mg/kg, 5 days/week for 4 weeks.?Paclitaxel was subcutaneously injected twice weekly[1]. |
别名 | 4-[[4-[(3-氯-2-氟苯基)氨基]-7-甲氧基-6-喹唑啉基]氧基]-N-甲基-1-哌啶乙酰胺二富马酸盐 |
分子量 | 706.1 |
分子式 | C31H33ClFN5O11 |
CAS No. | 1196531-39-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/mL (42.49 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.4162 mL | 7.0811 mL | 14.1623 mL | 35.4057 mL |
5 mM | 0.2832 mL | 1.4162 mL | 2.8325 mL | 7.0811 mL | |
10 mM | 0.1416 mL | 0.7081 mL | 1.4162 mL | 3.5406 mL | |
20 mM | 0.0708 mL | 0.3541 mL | 0.7081 mL | 1.7703 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
AZD8931 diFuMaric acid 1196531-39-1 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR 4-[[4-[(3-氯-2-氟苯基)氨基]-7-甲氧基-6-喹唑啉基]氧基]-N-甲基-1-哌啶乙酰胺二富马酸盐 AZD-8931 diFuMaric acid Inhibitor inhibitor inhibit